News    |     Publications    |     Events

HSL

Gamma Medica Expands into European Breast Imaging Market Through Partnership with Medical Supplies Distributor, Hospital Services Limited

By | news | No Comments

Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced it has partnered with Hospital Services Limited (HSL), an established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM® Molecular Breast Imaging system in the United Kingdom, Ireland and the Channel Islands.

GMI Logo

Gamma Medica Partners With Medical Imaging, Inc. and Capital X-Ray, Inc. to Distribute LumaGEM® Molecular Breast Imaging to Women’s Breast Screening Centers

By | news | No Comments

Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that it has partnered with Medical Imaging, Inc. and Capital X-Ray, Inc., leading providers of medical imaging equipment, to give women in Georgia, Louisiana, Alabama, Mississippi, Idaho and parts of Oregon, Montana, Wyoming and Washington State access to Gamma Medica’s LumaGEM® Molecular Breast Imaging (MBI) system.

major-hospital2

Gamma Medica, Alpha Imaging and Major Health Partners (MHP) Announce New Partnership to Provide First LumaGEM® in Indiana and First MBI at MHP Medical Center as a Secondary Breast Cancer Screening Option for Women with Dense Breast Tissue

By | news | No Comments

SHELBYVILLE, Ind. & Willoughby, Ohio & SALEM, N.H.–(BUSINESS WIRE)–Gamma Medica, a leader in molecular breast imaging (MBI) technology announced today that through its collaboration with Ohio-based Alpha Imaging, Indiana-based Major Health Partners (MHP) has purchased and installed Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system, the state’s first LumaGEM and the hospital’s first MBI. The MBI technology will be offered as a secondary screening and diagnostic tool following mammography, particularly for women with dense breast tissue. This proven imaging modality will enhance early breast cancer detection for women who face a greater risk of breast cancer.

screen-shot-2016-12-06-at-11-19-46-am

Gamma Medica Announces New Partnership with Leading Medical Facility, Einstein Medical Center Philadelphia, to Bring the First Clinical LumaGEM® Molecular Breast Imaging Technology to Pennsylvania

By | news | No Comments

SALEM, N.H. & PHILADELPHIA–(BUSINESS WIRE)–Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Einstein Medical Center Philadelphia has committed to purchase Pennsylvania’s first clinical LumaGEM®Molecular Breast Imaging system. MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer. It is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection in women who are at a higher risk due to dense breast tissue.

Gamma Medica Honors Milestone Year for Groundbreaking MBI Breast Cancer Detection Solution at RSNA 2016

By | news | No Comments

2016 clinical evidence confirms that adding LumaGEM®Molecular Breast Imaging (MBI) to mammography as a secondary screening method is more than twice as effective as mammogram and ultrasound in detecting cancer for women with dense breast tissue

CHICAGO, IL – (Nov. 21, 2016) Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced several 2016 achievements for its LumaGEM Molecular Breast Imaging system at this year’s Radiological Society of North America (RSNA) annual meeting (booth #2871). Over the past year, this MBI system has grown in national prominence and expanded its user base through a major educational campaign on breast density called Be Certain and by driving irrefutable clinical results featured in a breakthrough clinical study. Read More

1329428212_0

Gamma Medica Announces New Partnership in the Fight Against Breast Cancer with Henry Ford Health System LP

By | news | No Comments

WEST BLOOMFIELD, Mich. & SALEM, N.H.–(BUSINESS WIRE)–Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Henry Ford Health System has purchased Gamma Medica’s LumaGEM Molecular Breast Imagingsystem. The system is set to be installed by the end of 2016 at Henry Ford West Bloomfield Hospital. The MBI technology will be offered as a secondary screening and diagnostic tool following X-ray mammography, particularly for women with dense breast tissue. This proven imaging modality will help improve cancer detection in women who are at greater risk of developing breast cancer.

29321456654_c1b20f89fb_o

In Salem, Ayotte Highlights Legislative Efforts in the Fight Against Breast Cancer

By | news | No Comments

MANCHESTER, NH – On Monday, U.S. Senator Kelly Ayotte visited Gamma Medica in Salem to discuss her bipartisan efforts to protect access to mammograms for women and improve detection.  Senator Ayotte’s visit was in advance of Breast Cancer Awareness Month, which begins in October. Gamma Medica is a women’s health company focused on overcoming the limitations of mammography and other screening modalities in the early detection of breast cancer. Read More

Breakthrough Clinical Study Confirms LumaGEM’s Molecular Breast Imaging (MBI)’s High Cancer Detection Rate in Dense Breast Tissue Following Cancer-Negative Mammograms

By | news | No Comments

Authors of American Journal of Roentgenology (AJR) study used the LumaGEM® MBI System on 1,696 women to detect 13 cancers missed by routine mammograms, reporting MBI yielded a high detection rate and low biopsy rate .

SALEM, NH – Aug. 1, 2016 – A breakthrough retrospective study in AJR’s August issue confirmed Gamma Medica’s molecular breast imaging (MBI) technology’s high incremental cancer detection rate of 7.7 cancers per thousand (7.7/1000) and overall clinical effectiveness as a secondary screening tool in finding 13 malignancies among 1,696 women with dense breast tissue following mammograms that read negative for cancer.[1]Approximately 85 percent of these cancers were confirmed to be node negative (with 7.6 percent being confirmed node positive, and 7.6 percent being unknown), indicating they were detected at an early stage and therefore presented a better prognosis. Read More

Screen Shot 2016-07-25 at 2.01.05 PM

Gamma Medica Launches Be Certain Campaign to Educate Women on Dense Breast Tissue

By | news | No Comments

SALEM, NH – May 5, 2016Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today it has launched the Be Certain campaign, featuring a dedicated microsite as the cornerstone of an initiative to spread awareness on breast density. Today, about half of all women in the United States have dense breast tissue, making them four to five times[1] more likely to develop breast cancer. Traditional screening technology alone is not advanced enough to accurately detect cancerous tumors for these women who have a higher intrinsic risk of developing cancer during the course of their lifetime. Read More

Screen Shot 2016-07-25 at 2.03.05 PM

Dr. Nathalie Johnson, M.D., FACS, Joins Gamma Medica’s Clinical Advisory Board

By | news | No Comments

SALEM, NH – April 16, 2016Gamma Medica, a leader in molecular breast imaging technology (MBI), announced today that Dr. Nathalie Johnson, M.D., FACS, of the Legacy Cancer Institute and the Legacy Breast Health Centers in Portland, Oregon has agreed to join the organizations’ clinical advisory board, currently comprised of distinguished clinicians and thought leaders with expertise in women’s health technologies and diagnostic imaging. Dr. Johnson and the board will provide strategic and clinical advice as Gamma Medica continues commercialization and enhancements of its LumaGEM® Molecular Breast Imaging system. Read More